Marburg vaccine trial launches: could this stop the deadly virus?

NCT ID NCT07425821

Recruiting now ⭐️ VACCINE ⭐️ Sponsor: International AIDS Vaccine Initiative Source: ClinicalTrials.gov ↗

First seen Feb 28, 2026 · Last updated May 01, 2026 · Updated 4 times

Summary

This study tests a new vaccine designed to protect against Marburg virus disease, a rare but severe illness. Researchers will give the vaccine to 112 healthy adults aged 18-50 to check if it is safe and triggers an immune response. The vaccine uses a modified virus to deliver a Marburg protein, and participants are monitored for side effects and antibody production.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MARBURG VIRUS DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

George Washington University
RECRUITING

Washington D.C., District of Columbia, 20052, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••
Johnson County Clin-Trials
RECRUITING

Lenexa, Kansas, 66219, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

MARBURG VIRUS DISEASE